To investigate the possibility that 3-hydroxy-3-methylglutaryl CoA (HMGCoA) reductase inhibitors ameliorate renal disease via direct effects on the tubulointerstitium, primary cultures of human proximal tubule cells (PTC) and renal cortical fibroblasts (CF) were exposed for 24 h to simvastatin (0.1-10 µmol/l) under basal conditions and in the presence of 1,000 ng/ml of cyclosporin (CsA), which we have previously shown to promote in vitro interstitial matrix accumulation at least partially via activation of local cytokine networks. Simvastatin, in micromolar concentrations, engendered cholesterol-independent inhibition of CF and PTC thymidine incorporation and cholesterol-dependent suppression of PTC apical Na⁺/H⁺ exchange (NHE) (ethylisopropylamiloride-sensitive apical ²²Na⁺ uptake). Similarly, CF secretion of insulin-like growth factor-I (IGF-I) and IGF binding protein-3 were depressed, whereas CF collagen synthesis ([³H]proline incorporation) and PTC secretion of the fibrogenic cytokines, transforming growth factor-1, and platelet-derived growth factor were unaffected. A lower concentration (0.1 µmol/l) of simvastatin did not affect any of the above parameters under basal conditions but completely prevented CsA-stimulated CF collagen synthesis (control, 6.6 ± 0.6; CsA, 8.3 ± 0.6; CsA+simvastatin, 6.2 ± 0.5%; P < 0.05) and IGF-I secretion (89.5 ± 16.6, 204.7 ± 57.0, and 94.6 ± 22.3 ng · mg protein¹ · day¹, respectively; P < 0.05). The results suggest that simvastatin exerts direct cholesterol-dependent and -independent effects on the human kidney tubulointerstitium. HMGCoA reductase inhibitors may ameliorate interstitial fibrosis complicating CsA therapy via direct actions on human renal cortical fibroblasts.

3-hydroxy-3-methylglutaryl CoA reductase; insulin-like growth factor-I; insulin-like growth factor binding proteins; platelet-derived growth factor; transforming growth factor-